For which non-asthma condition is omalizumab indicated in selected cases?

For which non-asthma condition is omalizumab indicated in selected cases?

• A. Chronic idiopathic urticaria.
• B. Allergic rhinitis.
• C. Atopic dermatitis.
• D. Chronic obstructive pulmonary disease.

Answer: (A)

Omalizumab works by binding free IgE and reducing the activation of mast cells and basophils. In chronic spontaneous (idiopathic) urticaria, the wheals and itch come from mast cell degranulation and histamine release that can occur even without a known allergen. By lowering circulating IgE and downregulating FcεRI expression on these effector cells, omalizumab makes them less reactive, which translates into fewer hives and less itching for patients who remain symptomatic despite optimized antihistamine therapy. That specific use—helping chronic spontaneous urticaria that doesn’t respond adequately to standard antihistamines—explains why this is the non-asthma condition in which omalizumab is indicated in selected cases. Other options don’t fit typical indications: allergic rhinitis is usually managed with intranasal steroids and antihistamines rather than omalizumab; atopic dermatitis has limited and not routinely approved evidence for omalizumab; COPD is not driven by IgE-mediated pathways and omalizumab isn’t a standard therapy for it.

Omalizumab works by binding free IgE and reducing the activation of mast cells and basophils. In chronic spontaneous (idiopathic) urticaria, the wheals and itch come from mast cell degranulation and histamine release that can occur even without a known allergen. By lowering circulating IgE and downregulating FcεRI expression on these effector cells, omalizumab makes them less reactive, which translates into fewer hives and less itching for patients who remain symptomatic despite optimized antihistamine therapy. That specific use—helping chronic spontaneous urticaria that doesn’t respond adequately to standard antihistamines—explains why this is the non-asthma condition in which omalizumab is indicated in selected cases.

Other options don’t fit typical indications: allergic rhinitis is usually managed with intranasal steroids and antihistamines rather than omalizumab; atopic dermatitis has limited and not routinely approved evidence for omalizumab; COPD is not driven by IgE-mediated pathways and omalizumab isn’t a standard therapy for it.